-
Brii Biosciences Presents Elebsiran Phase II Data at APASL 2025 Meeting
•
China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase II ENSURE study for elebsiran (BRII-835, VIR-2218) at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2025). Elebsiran, an investigational small interfering ribonucleic acid (siRNA), is being…
-
Brii Biosciences to Acquire Full Rights to BRII-179 from VBI Vaccines
•
China-based Brii Biosciences Ltd (HKG: 2137) has announced its intention to acquire the intellectual property (IP) and other assets related to BRII-179 from its US partner VBI Vaccines, Inc. and certain of its subsidiaries (VBI), as well as its creditor K2 VBI Equity Trust, LLC and K2 HealthVentures LLC. Comprehensive…
-
Brii Biosciences’ Elebsiran Shows Promising Results in Phase II ENSURE Study for Chronic HBV
•
China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase II ENSURE study for elebsiran (BRII-835, VIR-2218), an investigational small interfering ribonucleic acid (siRNA) therapy for chronic hepatitis B virus (HBV) infection. Phase II ENSURE Study Design and Initial FindingsThe active-controlled and randomized Phase II…
-
Brii Bioscience’s US Partner VBI Vaccines Initiates Bankruptcy Reorganization
•
Brii Biosciences Ltd (HKG: 2137), a biopharmaceutical company based in China, has announced that its US partner VBI Vaccines Inc. (OTCMKTS: VBIVQ) has commenced bankruptcy reorganization proceedings. Brii Bio has a history of licensing agreements with VBI, securing exclusive global rights to BRII-179 and Asia-Pacific rights to PreHevbri (excluding Japan)…
-
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer to Lead Pipeline Strategy
•
Brii Biosciences Ltd (HKG: 2137), a leading biotechnology company based in China, has announced the appointment of Dr. Brian Alvin Johns as the firm’s Chief Scientific Officer (CSO), effective from January 3, 2024. In his new role, Dr. Johns will be responsible for overseeing the company’s discovery programs and charting…
-
Shionogi’s Acquisition of Qpex Impacts Brii Biosciences’ Rights to Anti-infective Drugs
•
Japan’s Shionogi & Co., Ltd (TYO: 4507) announced on June 26, 2023, its planned acquisition of US anti-infectives specialist Qpex Biopharma Inc., for USD 100 million upfront and an additional USD 40 million based on certain development and regulatory milestones. This deal has significant implications for China-based biotech Brii Biosciences…
-
Brii Biosciences Initiates Phase I Study for BRII-297 in Australia
•
China’s Brii Biosciences (HKG: 2137) has announced the first patient dosing in a Phase I clinical study assessing the safety, tolerability, and pharmacokinetics of its BRII-297 in healthy subjects in Australia. This marks a significant step in the development of the drug candidate, which is being closely watched for its…
-
Brii Biosciences Halts Development of Antibody Cocktail for COVID-19 Treatment
•
Brii Biosciences has announced a strategic decision to end the manufacturing and further development of the amubarvimab/romlusevimab combination treatment regimen for COVID-19. According to the company’s recent 2022 financial report, the antibody cocktail had been commercially available in China from July 2022 following an emergency use authorization (EUA) and had…
-
Brii Biosciences Reports Positive Phase I Results for HIV Treatments BRII-732 and BRII-778
•
China-based Brii Biosciences Limited (HKG: 2137) has published the latest results of two Phase I clinical studies assessing its long-acting BRII-732 and BRII-778, both being developed to treat HIV infection, in healthy subjects in the US. The results showed that both BRII-732 and BRII-778 produced good safety and tolerability profiles…
-
Brii Biosciences Publishes Positive Phase I Results for PPD Therapy BRII-296
•
China-based Brii Biosciences Limited (HKG: 2137) has published the top-line results from a Phase I study for its long-acting, single-injection therapy for postpartum depression (PPD), BRII-296. The open-label, single ascending dose Phase I study assessed the safety, tolerability, and pharmacokinetics (PK) of BRII-296 as a single-injection treatment option for PPD…
-
Everest Medicines Appoints Rogers Yongqing Luo as New CEO
•
China-based biotech Everest Medicines (HKG: 1952) has announced the appointment of a new CEO, Rogers Yongqing Luo, effective immediately. Luo replaces Dr. Kerry Blanchard, who resigned in August this year. Luo’s Background and ExperienceLuo joins Everest Medicines from Brii Biosciences, where he served as president and General Manager (GM) for…
